Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

Journal of Clinical Psychopharmacology

Volumn 17, Issue 4, 1997, Pages 298-307

  Chouinard, Guy ^a,c   Albright, Penny S ^b  

^a Allan Memorial Institute   (Canada)

^b Janssen Ortho Inc   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; RISPERIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TECHNIQUE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CANADA; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030812071     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199708000-00010     Document Type: Article

References (26)

1. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
2. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychol Bull 1990;14:522-5.
3. Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic cost of schizophrenia Arch Gen Psychiatry 1985; 42:537-43.
4. Wyatt RJ, de Saint Ghislain I. Economic savings and clozapine [letter]. Am J Psychiatry 1995;152:650-1.
5. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-4.
6. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies M, Snitz B. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8.
7. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
9. Marder SR, Meibach RL. Risperidone in the treatment of schizophrenia Am J Psychiatry 1994;13:25-40.
10. Coons SJ, Kaplan RM. Assessing health-related quality of life: application to drug therapy. Clin Ther 1992;14:850-8.
11. Detsky AS, Naglie G. A clinician's guide to cost effectiveness analysis. Ann Intern Med 1990;113:147-54.
12. Jueschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. Pharmacoeconomics 1992;1:84-94.
13. Detsky A. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1991.
14. Kay SR, Fiszbein A, Opler LA, The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 1987;13:261-76.
15. Chouinard G, Ross-Chouinard A, Annable L, Mercier P. The extrapyramidal symptom rating scale [abstract]. Can J Neurol Sci 1980;7:233.
16. Torrance GW. Utility approach to measuring health related quality of life. J Chronic Dis 1987;40:593-600.
17. Frobert DG, Kane RL. Methodology for measuring health state preferences, III: population and context effects. J Clin Epidemiol 1989;42:585-92.
18. Drummond M, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. Toronto: Oxford University Press, 1987.
19. Torrance GW, Boyle MH, Harwood SP. Applications of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982;30:1043-69.
20. Statistics Canada. Life tables: Canada and provinces, 1985-1987. Health Reports. Ottawa: Information Canada. Pubucation No. 41004.
21. Laupacis A, Feeny D, Detsky AS, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992;146:473-81.
22. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenia patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.
23. Albright PS, Livingstone S, Keegan D, Ingham M, Shrikhande S, Le Loner J. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retro-spective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;5:289-99.
24. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-4.
25. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55[suppl B]:161-5.
26. Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia Pharmacoeconomics 1993;4:131-56.